SEC Form 4 · accession 0001179110-18-012450
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald McMahon Ph.D.
Director
Period of report
Nov 1, 2018
Accepted (ET)
Nov 2, 2018 · 7:50 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001F1,F2 | Nov 1, 2018 | F | 2,888 | $0.3145 | D | 183,521 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On November 28, 2016, in connection with the Reporting Person's employment severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock. par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.
- F2Pursuant to the Severance Agreement, on November 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.